- Home
- ASGI vs AMLX Comparison
ASGI vs AMLX Comparison
Compare ASGI & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ASGI | AMLX |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 753.6M | 1.5B |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ASGI | AMLX |
|---|---|---|
| Price | $22.72 | $14.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $20.11 |
| AVG Volume (30 Days) | 188.0K | ★ 821.1K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 65.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $380,786,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1612.94 |
| 52 Week Low | $16.65 | $3.11 |
| 52 Week High | $25.95 | $17.49 |
Technical Indicators
Market Signals| Indicator | ASGI | AMLX |
|---|---|---|
| Relative Strength Index (RSI) | 48.95 | 56.80 |
| Support Level | $21.93 | $13.36 |
| Resistance Level | $22.92 | $15.37 |
| Average True Range (ATR) | 0.71 | 0.71 |
| MACD | -0.01 | 0.07 |
| Stochastic Oscillator | 49.23 | 91.88 |
Price Performance
Historical ComparisonAbout ASGI abrdn Global Infrastructure Income Fund of Beneficial Interest
abrdn Global Infrastructure Income Fund is a non-diversified, closed-end management investment company. Its objective is to seek to provide a high level of total return with an emphasis on current income by investing in assets that provide necessary services to society.
About AMLX Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.